Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial

Published:2023-12-02 Issue:12 Volume:23 Page:1287-1297
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Wessels Hendrik¹,von Richter Oliver²,Velinova Maria³,Höfler Josef⁴,Chamberlain Paul⁵,Kromminga Arno⁶,Lehnick Dirk⁷,Roth Karsten¹

Affiliation:

1. Polpharma Biologics S.A, Gdansk, Poland

2. Hexal AG (A Sandoz company), Holzkirchen, Germany

3. Early Development Services, ICON, Groningen, The Netherlands

4. Staburo GmbH, Munich, Germany

5. bioLOGICA Consulting, Arthez d’Asson, France

6. Kromminga Consulting, Hamburg, Germany

7. Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland

Funder

Polpharma Biologics S.A

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2290530

Reference34 articles.

1. Biogen Netherlands B.V. Tysabri® (natalizumab). Summary of Product Characteristics 2022. [Internet]. [cited 2023 Apr 6]. Available from: https://www.ema.europa.eu/documents/product-information/tysabri-epar-product-information_en.pdf.

2. Biogen Inc. Tysabri® (natalizumab). Prescribing Information. [Internet]. 2023 [cited 2023 Oct 2]. Available from: https://www.tysabri.com/content/dam/commercial/tysabri/pat/en_us/pdf/tysabri_prescribing_information.pdf

3. The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis

4. Natalizumab and Impedance of the Homing of CD34⁺ Hematopoietic Progenitors

5. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF